The National Comprehensive Cancer Network (NCCN) clinical practice guidelines have explicitly indicated that patients with CRC and KRAS mutations are resistant to anti-EGFR monoclonal antibody therapy [4]. The gene discussed is KRAS; the disease is colorectal carcinoma.